Company Update: Abbott Laboratories (NYSE:ABT) – Abbott Reports First-Quarter 2016 Results

[PR Newswire] – ABBOTT PARK, Ill., April 20, 2016 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2016. Adjusted diluted EPS from continuing operations, which … Read more on this. Abbott Laboratories (ABT) , currently valued at $64.56B, started trading this morning at $44.48. During the trading session, ABT traded between $43.53 to $44.58 with the price of the stock fluctuating between $36.00 to $51.74 over the last 52 weeks. ABT shares are currently priced at 20.30x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -5.15x earnings multiple for the same period. The company pays shareholders $1.04 per share in dividend income per year, for a current yield of 2.40%. According to a consensus of 20 analysts, the earnings estimate of $0.39 per share would be $0.08 worse than the year-ago quarter and a $0.10 sequential decrease. What we find to be interesting is that the full-year EPS estimate of $2.16 is a $0.01 better when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $4.78 Billion. If realized, that would be a 2.45% decrease over the year-ago quarter. Recently, Morgan Stanley downgraded ABT from Overweight to Equal-Weight (Jan 4, 2016). Previously, Goldman downgraded ABT from Buy to Neutral. When considering if the stock is under or overvalued, the average price target is $45.47, which is 2.23% above where the stock opened this morning. See more in (NYSE:ABT) Similar Articles: Company Update: Abbott Laboratories (NYSE:ABT) – Abbott Declares 369th Consecutive Quarterly Dividend Market Update: Abbott Laboratories (NYSE:ABT) – Abbott Labs to buy diagnostics company Alere for $5.8 bln Company Update: Abbott Laboratories (NYSE:ABT) – Abbott Reports Third-Quarter 2015 Results